The Non-glycemic Effects of SGLT2 Inhibitor / 임상당뇨병
Journal of Korean Diabetes
;
: 151-157, 2014.
Article
Dans Coréen
| WPRIM
| ID: wpr-726969
ABSTRACT
Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been introduced as a new class of anti-diabetic agents. In addition to their glycemic action, SGLT2 inhibitors also have a number of non-glycemic effects that may contribute to renal and/or cardiovascular benefits. These include effects on tubuloglomerular feedback in the kidney, body weight, blood pressure, and serum uric acid. Other non-glycemic effects of SGLT2 inhibitors that need to be further studied include the effects on lipid profiles, food intake, and secretion of hormones such as leptin, incretins, and aldosterone. Also, the exact mechanisms of various non-glycemic actions should be further studied. Additionally, SGLT2 inhibitor therapy in combination with other drugs may have beneficial glycemic and non-glycemic effects.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Sodium
/
Acide urique
/
Pression sanguine
/
Poids
/
Leptine
/
Diabète
/
Consommation alimentaire
/
Aldostérone
/
Incrétines
/
Glucose
langue:
Coréen
Texte intégral:
Journal of Korean Diabetes
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS